ClinicalTrials.gg
Active, not recruitingNCT07193472Updated Sep 25, 2026

Serratus Intercostal Plane Block Versus Port Infiltration in Laparoscopic Cholecystectomy

An interventional study of serratus intercostal plane block as analgesic technique in Postoperative Pain, sponsored by Hospital del Rio Hortega. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Hospital del Rio Hortega · Not applicable, Interventional, and Treatment

How we know

Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Pain, Postoperative with a site in Spain — 18 open to participants now, 23 under way, 1 of them phase 3. Pain, Postoperative · Spain.

Planned enrollment
21st of 60
128 · median 90
Started
2025
with 5 others
No phase
30 of 86
13 open now
Primary completion
2026-12
later than 17 of 22 live
Registered
75th of 86
by date

Among the 86 studies in Pain, Postoperative with a site in Spain, this one is the 21st largest by planned enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2025, is one of 30 with no phase, reaches primary completion later than 17 of the 22 other live ones, and was the 75th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

18 of the 86 studies in Pain, Postoperative with a site in Spain are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Pain, Postoperative with a site in Spain, or all of them as a file.
02

Study summary

Most patients undergoing laparoscopic cholecystectomy (LC) experience moderate to severe pain in the first 24 hours after surgery. Port infiltration is the usual analgesic method while serratus-intercostal plane blockade (SIPB) has shown its efficacy in open cholecystectomy pain control. The aim of the present study was to compare the efficacy of both techniques in pain control.

OBJECTIVE The prospective randomised study has the working hypothesis is based on evaluating whether serratus-intercostal block (modified BRILMA) is equal or superior to laparoscopic port infiltration (PI) in terms of quality of postoperative recovery and pain control.

Secondary objectives of the study will be to assess the absence of adverse effects.

MATERIAL AND METHODS the investigators present a low-intervention clinical trial. The sample will be composed of 128 patients divided into two groups according to the analgesic technique (serratus-intercostal and port infiltration), following a 1:1 randomisation, consecutively until the sample size is reached and fulfilling the following criteria: signature of informed consent, over 18 years of age, ASA I-III, undergoing laparoscopic cholecystectomy.

Intraoperatively, patients will receive standard monitoring and induction. Analgesia will consist of a multimodal strategy (8 mg dexamethasone, 1 g paracetamol and 50 mg dexketoprofen pre-incisionally, intraoperative fentanyl on demand and the corresponding regional technique).

In the postoperative period, the main variable to be evaluated in forms designed for this purpose will be the difference in pain assessed by means of an numeric rating scale (NRS scale) and the quality of recovery will be measured by means of the modified Postoperative Quality of Recovery Score (QoR-15 ) recovery scale (15 responses).

Read the detailed description

Background

Postoperative pain remains a significant concern following laparoscopic cholecystectomy (LC), with most patients experiencing moderate to severe pain within the first 24 hours. Traditionally, port-site infiltration (PI) with local anesthetics is employed for analgesia. However, the serratus-intercostal plane block (SIPB), also known as the modified BRILMA block, has demonstrated efficacy in pain management for open cholecystectomy. Its role in LC remains to be clarified.

Objective

The primary objective of this prospective randomised study is to evaluate whether SIPB (modified BRILMA block) provides equivalent or superior postoperative analgesia and quality of recovery compared to port-site infiltration in patients undergoing LC.

Secondary objective: To assess the incidence of adverse effects related to each analgesic technique.

Methods

This study is designed as a low-intervention, prospective, randomized clinical trial. A total of 128 adult patients (ASA I-III) scheduled for elective laparoscopic cholecystectomy will be randomly allocated (1:1) to receive either serratus-intercostal plane block or laparoscopic port infiltration for perioperative analgesia. Randomization will be performed consecutively until the target sample size is reached.

Inclusion Criteria:

Age ≥ 18 years

ASA physical status I-III

Informed consent provided

Exclusion Criteria:

(Coagulopaty, allergy to local anaesthetic, history of chronic pain)

Intraoperative Management:

All patients will receive standardized general anesthesia and multimodal analgesia comprising:

8 mg dexamethasone

1 g paracetamol

50 mg dexketoprofen (administered pre-incisionally)

Fentanyl as needed during surgery

Assigned regional analgesic technique (SIPB or PI)

Postoperative Evaluation:

Primary Outcome Measures:

Pain intensity using the Numerical Rating Scale (NRS) at predefined intervals

Quality of recovery assessed via the modified QoR-15 questionnaire

Secondary Outcome Measure:Incidence of adverse events or complications related to the analgesic techniques

SIPB group: receive The Serratus intercostal plane block as analgesic technique after induction. With the patient lying in supine position, the local anaesthetic is administered in the plane under Serratus muscle at the 8th rib level Infiltration group: in this group the surgeons administered local anaesthetic after inserting the trocar.

Conclusion (anticipated)

This trial aims to determine whether SIPB offers superior analgesic efficacy and recovery quality compared to standard port infiltration in LC, potentially informing improved postoperative pain protocols.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -III
  • laparoscopic cholecystectomy

Exclusion criteria

Exclusion Criteria:

  • Alergy to used drugs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Other
    port infiltration

    patients receiving port infiltration as analgesia

    Procedure: serratus intercostal plane block as analgesic technique

Interventions

  • Procedureserratus intercostal plane block as analgesic technique

    the SIPB will be applied after starting surgery and before general anaesthesia

06

What researchers measure

Primary outcomes

  1. efectiveness of analgesia (SIPB versus IP)

    The working hypothesis is based on evaluating whether serratus-intercostal block (modified BRILMA) is equal or superior to laparoscopic port infiltration (PI) in terms of quality of postoperative recovery (QoR15) and pain control (NRS) 0-10

    Time frame: one year

Secondary outcomes

  1. side efects

    assesment of side efects

    Time frame: one year

  2. Postoperative pain control

    Pain developed for patients after surgery first 24 h . nRS 0-10

    Time frame: One year

  3. Postoperative recovery

    Intake, rest at night, walking…assessed with QoR15 0- 150

    Time frame: One year

07

Study locations

1 site
  • Fernandez
    Valladolid, Valladolid 47008, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 18 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Sep 25, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2026was Dec 2025
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2026
Sep 25, 2026
Study completion
Dec 31, 2025→Dec 31, 2026
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Dec 31, 2025→Dec 31, 2026
    Study completion Dec 31, 2025→Dec 31, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07193472
Lead sponsor
Hospital del Rio Hortega
Responsible party
María Teresa Fernandez (MD, principal investigator, Hospital del Rio Hortega) — Principal investigator
First posted
Sep 25, 2025
Start date
Jun 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 25, 2026

Study contacts

Maria Teresa Fernandez, MD
principal investigator · Hospital del Rio Hortega

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion